联合利多卡因和艾司氯胺酮的无阿片化麻醉方法与传统麻醉方法对小儿围术期呼吸系统并发症发生率影响的研究:一项随机对照试验

注册号:

Registration number:

ChiCTR2500105161 

最近更新日期:

Date of Last Refreshed on:

2025-06-30 14:53:28 

注册时间:

Date of Registration:

2025-06-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

联合利多卡因和艾司氯胺酮的无阿片化麻醉方法与传统麻醉方法对小儿围术期呼吸系统并发症发生率影响的研究:一项随机对照试验

Public title:

Study on the Effects of opioid-free anesthesia combined with lidocaine and esketamine and traditional anesthesia methods on the incidence of perioperative respiratory complications in Children: A randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

联合利多卡因和艾司氯胺酮的无阿片化麻醉方法与传统麻醉方法对小儿围术期呼吸系统并发症发生率影响的研究:一项随机对照试验

Scientific title:

Study on the Effects of opioid-free anesthesia combined with lidocaine and esketamine and traditional anesthesia methods on the incidence of perioperative respiratory complications in Children: A randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龚园 

研究负责人:

龚园 

Applicant:

Yuan Gong 

Study leader:

Yuan Gong 

申请注册联系人电话:

Applicant telephone:

+86 139 8674 6821

研究负责人电话:

Study leader's
telephone:

+86 139 8674 6821

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gy-yc@163.com

研究负责人电子邮件:

Study leader's E-mail:

gy-yc@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省宜昌市伍家岗区夷陵大道183号

研究负责人通讯地址:

湖北省宜昌市伍家岗区夷陵大道183号

Applicant address:

No. 183 Yiling Avenue,Wujiagang District, Yichang city,China

Study leader's address:

No. 183 Yiling Avenue,Wujiagang District, Yichang city,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宜昌市中心人民医院

Applicant's institution:

Yichang Central People's Hospital

研究负责人所在单位:

宜昌市中心人民医院

Affiliation of the Leader:

Yichang Central People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-159-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宜昌市中心人民医院医学伦理委员会

Name of the ethic committee:

Yichang Central People's Hospital Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-22 00:00:00

伦理委员会联系人:

王珊珊

Contact Name of the ethic committee:

Wang Shanshan

伦理委员会联系地址:

湖北省宜昌市夷陵大道183号

Contact Address of the ethic committee:

183 Yiling Avenue, Yichang City, Hubei Province,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 717681150

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宜昌市中心人民医院

Primary sponsor:

Yichang Central People's Hospital

研究实施负责(组长)单位地址:

湖北省宜昌市伍家岗区夷陵大道183号

Primary sponsor's address:

No. 183 Yiling Avenue,Wujiagang District, Yichang city,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

宜昌市中心人民医院

具体地址:

湖北省宜昌市伍家岗区夷陵大道183号

Institution
hospital:

Yichang Central People's Hospital

Address:

No. 183 Yiling Avenue,Wujiagang District, Yichang city,China

经费或物资来源:

陈孝平基金

Source(s) of funding:

Chen Xiaoping Fund

研究疾病:

围术期呼吸系统并发症  

Target disease:

Perioperative respiratory system complications

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(一)主要目的 比较两种无阿片化药物与传统阿片方案的呼吸不良事件的发生率差异 (二)次要目的 比较两种无阿片化药物与传统阿片方案的疼痛的发生率差异  

Objectives of Study:

(1) Main purpose: To compare the incidence differences of adverse respiratory events between two non-opioid drugs and the traditional opioid regimen (2) Secondary objective: To compare the incidence of pain between two non-opioid drugs and the traditional opioid regimen

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)无知情同意 (2)在住院期间同时进行其他手术 (3)存在合并症或ASA分级II级以上 (4)长期使用任何类型的药物

Exclusion criteria:

1) No informed consent 2) Other surgeries are performed simultaneously during hospitalization 3) There are comorbidities or ASA grade II or above 4) Long-term use of any type of medication

研究实施时间:

Study execute time:

From 2025-06-30 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-30 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

阿片化组

样本量:

90

Group:

Opioid group

Sample size:

干预措施:

舒芬太尼0.25ug/kg&生理盐水以相同速度静脉注射,并持续泵注曲马多1mg/kg&布洛芬10mg/kg至手术结束

干预措施代码:

Intervention:

Sufentanil at 0.25ug/kg and normal saline were intravenously injected at the same rate, and tramadol at 1mg/kg and ibuprofen at 10mg/kg were continuously pumped until the end of the surgery

Intervention code:

组别:

无阿片化组

样本量:

90

Group:

Non-opioid group

Sample size:

干预措施:

利多卡因1.0mg/kg&艾司氯胺酮0.2mg/kg静脉注射并以2mg/kg·h持续泵注至手术结束

干预措施代码:

Intervention:

Lidocaine at 1.0mg/kg and esketamine at 0.2mg/kg were intravenously injected and continuously pumped at 2mg/kg·h until the end of the surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

宜昌市中心人民医院 

单位级别:

三甲 

Institution
hospital:

Yichang Central People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

围手术期呼吸不良事件(PRAE)

指标类型:

主要指标

Outcome:

Perioperative Adverse respiratory Events (PRAE)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛

指标类型:

次要指标

Outcome:

Postoperative pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后谵妄

指标类型:

次要指标

Outcome:

Postoperative delirium

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

基线和插管后5分钟血流动力学

指标类型:

次要指标

Outcome:

Hemodynamics at baseline and 5 minutes after intubation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

耶鲁术前焦虑量表(mYPAS)评分

指标类型:

次要指标

Outcome:

Yale Preoperative Anxiety Scale (mYPAS) score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 6 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

使用SPSS软件对入选患者进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized grouping of selected patients using SPSS software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

研究实施者和研究对象均不知道分组和用药情况。

Blinding:

Neither the research implementer nor the research subjects knew the grouping and medication situation.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

允许向通讯作者提出的合理要求的人员使用和/或分析本研究的数据集。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Access to and/or analysis of the data set for this study is permitted by persons who make reasonable requests to the corresponding authors.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表和电子管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical records and electronic management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-30 14:53:24